Результаты поиска

Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges.

Ureteral involvement by diffuse large B-cell lymphoma (DLBCL) is an extremely rare clinical entity that can mimic primary urothelial carcinoma and pose a significant diagnostic challenge. A 70-year-old female patient initially presented to a urologist with renal colic. The patient denied fever, night sweats, unintentional weight loss, or prior hematologic disorders, and no peripheral lymphadenopathy was detected on physical examination. Multislice computed tomography (MSCT) revealed a ureteral mass, followed by cystoscopy with ureteral stent placement. Due to the strong clinical and radiologic

Совпадение в полном тексте источника
… The most common adverse effects of the R-CHOP regimen include myelosuppression (neutropenia, anemia, and thrombocytopenia), alopecia, nausea and vomiting, peripheral neuropathy (most often due to vincristine), cardiotoxicity (due to doxorubicin), and an increased risk of infections due to immunosuppression …

Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.

PatientFemale, 58.Final diagnosisAcute hear failure.SymptomsDispnoea • edema • fatigue.Medication—Clinical procedureBone marrow biopsy • endomyocardial biopsy • abdominal subcutaneous fat biopsy under ECMO support.SpecialtyCardiology.ObjectiveRare disease.BackgroundCardiac amyloidosis results from the amyloid deposition in heart tissue, either in the context of a systemic disease or as a localized form. Several pro-amyloid proteins can produce amyloid deposits in the heart. Each of these amyloidoses has characteristic clinical (cardiac and extracardiac) features, and a specific diagnosis and t

Совпадение в полном тексте источника
… None of these options were considered to be suitable by the multidisciplinary team, taking into account the following reasons: i) bortezomib and melphalan have high cardiotoxicity and are associated with worsening fluid retention and congestive heart failure [ 8 ]; ii) in patients with severe cardiac …

Perspectives on the Treatment of Multiple Myeloma.

The treatment of multiple myeloma has evolved significantly over the past few decades with the development of novel therapeutics. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and high-dose chemotherapy followed by hematopoietic stem cell transplantation has led to improved response rates and survival outcomes. The use of bispecific antibodies and chimeric antigen receptor T-cell therapy is currently under study, and early results are showing promise. Although outcomes for patients with MM have improved with the development of new treatments, there r

Совпадение в полном тексте источника
… Treatment-related deaths occurred in 2 patients (<1%) in the RVD group (one due to cardiotoxicity and one due to secondary cancer) and in 11 (2%) in the KRD group (4 due to cardiotoxicity, 2 due to acute kidney failure, one due to liver toxicity, 2 due to respiratory failure, one due to thromboembolic …

Несоответствия в рецидивной или рефрактной множественной миеломе: рекомендации межпрофессиональной консенсусной группы.

Во многих исследованиях были зафиксированы расовые, социально-экономические, географические и другие различия для пациентов из Соединенных Штатов (США) с множественной миеломой, связанные с диагностикой и управлением прифронтовыми линиями. В отличие от этого, очень мало известно о различиях в регулировании рецидивов/изъятий множественной миеломы (RRMM), несмотря на множество новых вариантов лечения. В ходе этого обзора мы обсуждаем проявления неравенства в ПРМ и стратегии по смягчению их воздействия. Лекарства от иммуномодулирующих препаратов могут создавать различия по многим осям, например н

Совпадение в полном тексте источника
… Unlike bortezomib or carfilzomib, IMiD-associated neuropathy is less common and IMiD-associated cardiotoxicity (e.g., arterial thromboembolic events) is quite rare. … Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes. J Am Heart Assoc. 2021;10:e023852 10.1161/JAHA.121.023852. 10.1161/JAHA.121.023852 97. Camilli M, La Vecchia G, Lillo R, Iannaccone G, Lamendola P, Montone RA, et al. …

Recent advances in the diagnosis and management of amyloid cardiomyopathy.

Amyloidosis is a disorder characterized by misfolded precursor proteins that form depositions of fibrillar aggregates with an abnormal cross-beta-sheet conformation, known as amyloid, in the extracellular space of several tissues. Although there are more than 30 known amyloidogenic proteins, both hereditary and non-hereditary, cardiac amyloidosis (CA) typically arises from either misfolded transthyretin (ATTR amyloidosis) or immunoglobulin light-chain aggregation (AL amyloidosis). Its prevalence is more common than previously thought, especially among patients with heart failure and preserved

Совпадение в полном тексте источника
… The discrepancy has been attributed to the direct cardiotoxicity of circulating free light-chains (FLCs) and pre-fibrillar aggregates in CA caused by AL amyloidosis 2 , 4 . The presence and extent of cardiac involvement is a major determinant of outcome in both AL amyloidosis and ATTR amyloidosis. … Doxycycline, a tetracycline antibiotic, may mitigate the cardiotoxic effects of light-chain amyloid fibril deposition in the extracellular cardiac environment. …

Role of Physical Activity and Cardiac Rehabilitation in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Hematopoietic stem cell transplantation (HSCT) is a standard treatment for several malignancies, and >50,000 HSCT are performed annually worldwide. As survival after HSCT improves, cardiovascular disease and associated risk factors have gained importance as a significant cause of morbidity and mortality in this cohort. In this article, we detail the risk factors for cardiovascular disease and their impact in patients undergoing HSCT. Additionally, we critically review the data on the impact of physical exercise in patients undergoing HSCT. Although limited by significant heterogeneity in metho

Совпадение в полном тексте источника
… They proposed the development of a comprehensive model (i.e., cardio-oncology rehabilitation) to identify oncology patients at high risk of CVD, including cardiotoxicity related to cancer therapies, and using the multimodality approach of CR (e.g., exercise plus nutritional counseling and cardiovascular … Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–763. 22. Tichelli A., Bucher C., Rovo A. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463–3471. doi: 10.1182/blood-2006-10-054080. 23. …

Light Chain Amyloidosis.

Light chain (AL) amyloidosis is caused by a usually small plasma-cell clone that is able to produce the amyloidogenic light chains. They are able to misfold and aggregate, deposit in tissues in the form of amyloid fibrils and lead to irreversible organ dysfunction and eventually death if treatment is late or ineffective. Cardiac damage is the most important prognostic determinant. The risk of dialysis is predicted by the severity of renal involvement, defined by the baseline proteinuria and glomerular filtration rate, and by the response to therapy. The specific treatment is chemotherapy targe

New light on chemotherapy toxicity and its prevention.

Most patients with cancer receive chemotherapy. Unfortunately, chemotherapy is associated with a number of potentially life-threatening side effects. There is a need to ameliorate chemotoxicity to improve therapeutic outcomes and quality of life. Chemotoxicity arises from systemic DNA damage and inflammation in healthy cells due to chemotherapy drugs. Traditionally, these processes are believed to be caused by the direct death of normal cells by chemotherapeutic drugs. However, new research has challenged this dogma by suggesting that chemotoxicity is a secondary effect associated with the rel

Совпадение в полном тексте источника
… Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474–502. 6. Winter SF, Jo J, Schiff D, Dietrich J. Central nervous system complications among oncology patients. Hematol Oncol Clin North Am. 2022;36:217–36. 7. …

Keyword Index for Volume 105

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… cancer risk 1230 cancer screening 475 cancer stem cells 212, 1253, 1759 cancer survivors 1158 cancer treatment 1295 cancer type 1814 cancer-associated fibroblasts 996, 1224 cancer-free survival 460 capecitabine 58, 206, 505, 1273 carboplatin 897 carcinoma 694, 1396 cardiac biomarkers 1663 cardiotoxicity …

A narrative review on trazodone as a multimodal and multifunctional antidepressant: clinical relevance of formulations, dosing, and pharmacokinetic/pharmacodynamic targets.

BackgroundTrazodone, an antidepressant, has only been approved for use in major depressive disorder (MDD), but has demonstrated potent therapeutic potential in various conditions, such as insomnia and anxiety. It targets multiple serotonergic, adrenergic, and histaminergic receptors. Given this multimodal and multifunctional profile, we aimed to provide a comprehensive overview of the pharmacodynamic and pharmacokinetic properties of trazodone and its clinical applications across various conditions.Main textTrazodone demonstrates sedative and anxiolytic effects even at a low dose (25-75 mg) an

Совпадение в полном тексте источника
… suggests that trazodone may provide rapid symptom relief in the short term, but the benefits plateau with long-term use Special population: Elderly patients • Underdiagnosed depression in the elderly often presents as physical or cognitive complaints [ 46 ] • Minimal anticholinergic activity and low cardiotoxicity … suggests that trazodone may provide rapid symptom relief in the short term, but the benefits plateau with long-term use Special population: Elderly patients | • Underdiagnosed depression in the elderly often presents as physical or cognitive complaints [ 46 ] • Minimal anticholinergic activity and low cardiotoxicity …

Сексуальные и гендерные аспекты в миелоиде и лимфоболическом лейкемии и множественной миеломе: от молекулярных механизмов к клиническим результатам.

Биологические и гендерные факторы оказывают значительное влияние на патогенез, прогресс и реакцию на гематологическое заболевание. В настоящем всеобъемлющем обзоре рассматриваются различия по признаку пола в острой миелоидной лейкемии, острой лимфоболической лейкемии, хронической миэлоидной лейкемии и множественной миеломе на основе систематического анализа рецензируемой литературы, опубликованной между 2014-2024 и идентифицировался с помощью структурированного поиска баз данных PubMed, Web of Science и MedLINE. Эпидемиологические данные свидетельствуют о более высокой частотности заболеваний

Совпадение в полном тексте источника
… For example, in the treatment of acute myeloid leukemia, sex-specific polymorphisms in drug-metabolizing enzymes have been shown to affect both the efficacy and cardiotoxicity of anthracycline-based treatment [ 37 ]. … Treatment Response | Anthracycline cardiotoxicity varies by sex/life stage: Prepubertal females: Higher risk (RR 1.89, CI 1.28–2.78) Premenopausal females: Lower risk (16.5% vs. 7.3% hospitalization) Postmenopausal: No significant difference. …

Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review.

Purpose of reviewProviding rehabilitation to patients with cancer can be challenging due to the medical complexity associated with the illness and its treatments. This article provides the reader with a summary of frequently encountered medical conditions in the cancer population and associated safety considerations and precautions. An update on treatment modalities commonly used for symptom management is also presented.Recent findingsCancer and cancer treatments can cause changes in multiple organ systems. Special considerations and precautions are necessary to provide safe and effective reha

Совпадение в полном тексте источника
… Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia 17:474–502 7. Giuranno L, Ient J, De Ruysscher D, Vooijs MA (2019) Radiation-induced lung injury (RILI) 9:877 8. Lenneman CG, Sawyer DB. … Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118:1008–1020. doi: 10.1161/CIRCRESAHA.115.303633. 9. Peel AB, Thomas SM, Dittus K, Lee, Jones W, Lakoski SG Cardiorespiratory fitness in breast cancer patients: a call for normative values 10. …

Advances in the Treatment of Cardiac Amyloidosis.

Opinion statementCardiac amyloidosis is associated with a high mortality rate, a long delay between the first signs and the diagnosis but a short interval between diagnosis and death. This scenario has changed recently due to improved disease awareness among doctors and significant progress in diagnosis thanks to multimodal imaging and a multidisciplinary approach. Therefore, during the last few years, we have had access to specific therapies for those patients. Those therapies are quite different depending on the type of amyloidosis, but there has been real progress. Systemic light chain amyl

Совпадение в полном тексте источника
… It has been observed that this strain pattern, known as apical sparing or “cherry on top,” is not specific to CA, since it is also present in other conditions such as aortic stenosis, cardiotoxicity, and dilated cardiomyopathy. • The ejection fraction strain ratio (a ratio of LV ejection fraction/global … A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin Ther. 1997;19(1):167–184. doi: 10.1016/s0149-2918(97)80084-7. 56. …

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy.

Cancer therapies have advanced tremendously throughout the last decade, yet multiple factors still hinder the success of the different cancer therapeutics. The traditional therapeutic approach has been proven insufficient and lacking in the suppression of tumor growth. The simultaneous delivery of multiple small-molecule chemotherapeutic drugs and genes improves the effectiveness of each treatment, thus optimizing efficacy and improving synergistic effects. Nanomedicines integrating inorganic, lipid, and polymeric-based nanoparticles have been designed to regulate the spatiotemporal release of

Совпадение в полном тексте источника
… However, using DOX as a mono-therapeutic treatment usually causes severe side effects in normal tissues, especially cardiotoxicity. The reason behind the cardiotoxicity induced by DOX is still unclear. … To achieve a synergistic effect, overcome the MDR of DOX, and simultaneously tone down the cardiotoxicity, DOX is often used in combination with another chemotherapeutic drug. …

Keyword Index for Volume 91

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… cancer-related fatigue 822 cancer-testis antigen 1566 capecitabine 613, 834, 839, 1019, 1763, 2005 carbohydrate antigen 15-3 873 carboplatin 213, 627, 683, 1038, 1651 carcinoembryonic antigen 873 carcinoembryonic antigen-related cell adhesion molecule 6 1384 carcinogenesis 119, 195, 633 carcinoma 1515 cardiotoxicity …

Keyword Index for Volume 88

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… C4.4a 579 CA-19-9 1248 calcitonin 1537 cancer 163, 223, 270, 684 cancer immunotherapy 1292 cancer registries 1693 cancer susceptibility 487 cancer therapy 613 capecitabine 782 CAR 1411 carbonic anhydrase 1065 carcinogenesis 733, 740, 1217, 1501, 1735 carcinoma 702, 1543 carcinosarcoma 654 cardiotoxicity …

Neurocardiology Update: The Brain-Heart Connection in Multiple Sclerosis-A Narrative Review.

BACKGROUND AND AIMS: While multiple sclerosis (MS) is primarily considered a neurological disorder, mounting evidence suggests a strong association with cardiovascular diseases (CVDs), impacting both disease progression and patient outcomes. This paper aims to raise awareness of this disease association while promoting a clinical-oriented, multidisciplinary approach that can provide long-term benefits for these patients. METHODS: A comprehensive literature review was conducted to gather up-to-date evidence concerning the incidence and type of CVDs associated with MS, the mechanisms underlying

Совпадение в полном тексте источника
… Also, while not commonly used today, mitoxantrone is well‐known for its cardiotoxicity [ 49 ]. …

Эффективность неевроиммунной терапии, включая митоксиндолы, ангиотензин 1-7 и эндоканнабиноиды рака, аутоиммунной и нейродегенеративной болезни.

ЦЕЛЬ: Последние достижения в области психо-нейро-эндокринной-иммунологии свидетельствуют о том, что многочисленные неинфекционные заболевания (НИЗ) возникают в результате сбоев в функционировании иммунной сети цитокина, что приводит к хроническим подстрекательским реакциям. Эта устойчивая низколаминированная воспаление объясняется недостатками важнейших внутренних нейроноэндокринных систем против воспаления, включая синусовую железу, эндоканнабиноидную систему и ось ангиотенсина, предотвращающего фермент 2 / ангиотенсина 1-7. Управление сосновыми метоксиндолами (мелатонин, 5-метокситриптамин),

AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes.

BackgroundAutologous stem cell transplantation (ASCT) remains an effective treatment option for many patients with systemic light chain (AL) amyloidosis. While maintenance post ASCT in multiple myeloma is now standard, the decision to utilize maintenance in AL amyloidosis remains largely unexplored. The present study aims to determine the prognostic significance of utilizing maintenance therapy following ASCT and assess the impact of fluorescent in situ hybridization (FISH) abnormalities, bone marrow plasma cell burden (BMPC), and degree of organ involvement on this decision.Methods and result

Совпадение в полном тексте источника
… but may be related to our limited sample size and dataset, or potentially suggests that patients may derive minor immediate delay in progression of disease upfront with these maintenance therapies, but may ultimately incur cumulative side effects and toxicities related to their long-term use (i.e., cardiotoxicity …

Время отключения в слоях при мукозите и его ассоциация с системными осложнениями у пациентов с пересадкой гематопоэтических стволовых клеток: выводы из национального исследования в стационаре.

ОБЪЕКТ ИССЛЕДОВАНИЯ: Оральные узловатые мукозные инфекции (ОУМИ) являются частой и серьезной осложнением трансплантации гемопоэтических клеток (ТГК). Определено ли то, что длительное время выписки из больницы, используемое как прокси для увеличенного срока пребывания (СПП), идентифицирует большую системную морбидность у пациентов, которые развивают ОУМИ, остается неясным. Настоящее ретроспективное когортное исследование направлено на оценку, у пациентов с документированным ОУМИ среди получателей ТГК, длительное время выписки независимо связано с увеличением системных осложнений.МЕТОДЫ: Настоящ

Совпадение в полном тексте источника
… This distinction reflects known differences in treatment exposures: autologous recipients often have greater prior exposure to cardiotoxic agents, while allogeneic recipients experience prolonged immunosuppression and higher rates of endothelial injury and drug-related toxicities. … Congestive heart failure in autologous HCT may be driven by anthracycline-related cardiotoxicity, fluid shifts from parenteral nutrition, or sepsis-induced cardiomyopathy in the setting of prolonged hospitalization. …